Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
LXRX · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including LXRX · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | LXRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -11.0% | -4.3% | 34% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -10.4% | -0.8% | 29% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -10.0% | -2.3% | 28% | 20% | |
| Book yieldHigher is better · 587 reported | 26.8% | 25.9% | 51% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 313 | 255M USD | 8 | 36 | |
| 313 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 4.2B USD |
| 8 |
| 44 |
| 313 | 264M USD | 8 | 30 |
| 313 | 255M USD | 8 | 38 |
| 313 | 650M USD | 8 | 48 |
| 313 | 264M USD | 8 | 24 |
| 313 | 441M USD | 8 | 34 |
| 313 | 1.8B USD | 8 | 42 |
| 313 | 2.6B USD | 8 | 43 |